Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP

(LONN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Lonza Group AG : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/20/2017 | 09:15am EDT

The company will report its earnings for FY 2016 on 01/25/2017. Generally, the company reports earnings in line with the consensus. In recent months, the 9 analysts from Thomson Reuters consensus have revised their EPS estimates upward.

Annual earnings per share is expected at 7.45 CHF for 2016 (+ 41.7% from 2015). A summary of annual publications and estimates is available below.

Annual results2013201420152016 (e)2017 (e)
Sales
Million CHF
Released
Forecast
Spread
3 584
3 746
-4,3%
3 640
3 699
-1,6%
3 803
3 795
0,21%

4 038

4 278
Operating income (EBITDA)
Million CHF
Released
Forecast
Spread
711
664
7,0%
743
736
1,00%
793
786
0,95%

882

988
Operating profit (EBIT)
Million CHF
Released
Forecast
Spread
436
353
23%
475
444
7,1%
524
472
11%

598

686
Pre-Tax Profit (EBT)
Million CHF
Released
Forecast
Spread
105
209
-50%
279
289
-3,6%
341
385
-11%

474

630
Net income
Million CHF
Released
Forecast
Spread
87,0
174
-50%
237
238
-0,61%
277
309
-10%

386

468
EPS
 CHF
Released
Forecast
Spread
1,67
3,16
-47%
4,54
4,35
4,3%
5,26
6,04
-13%

7,45

9,31
Announcement Date01/23/201401/21/201501/27/2016

© MarketScreener.com 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LONZA GROUP
10/15GENMAB : Lonza's Ibex Solutions to Support Genmab's Growing Clinical Portfolio
AQ
10/08PREVAIL THERAPEUTICS : and Lonza Establish Strategic Collaboration to Develop an..
AQ
10/08TRACKINSIGHT : Performance boost from Swiss Stocks
TI
10/04LONZA : MODA-ES TM Platform helps Nephron Pharmaceuticals move from paper to an ..
AQ
10/02CELLECTIS : and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis :..
AQ
09/24LONZA : Launches Joint Health Consumer Education Campaign with New York Photogra..
AQ
09/10LONZA : Announces Refinancing Extension and Increase of Its Term and Revolving B..
AQ
09/10LONZA : Citryll and Lonza Enter Into Partnership to Manufacture NETosis Inhibiti..
AQ
09/03CELLTRION : and Lonza Sign Contract to Manufacture Remsima Drug Substance
AQ
09/03Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
More news
Financials (CHF)
Sales 2019 5 908 M
EBIT 2019 1 209 M
Net income 2019 736 M
Debt 2019 3 244 M
Yield 2019 0,85%
P/E ratio 2019 34,4x
P/E ratio 2020 28,8x
EV / Sales2019 4,80x
EV / Sales2020 4,45x
Capitalization 25 140 M
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 373,42  CHF
Last Close Price 338,60  CHF
Spread / Highest target 36,4%
Spread / Average Target 10,3%
Spread / Lowest Target -18,8%
EPS Revisions
Managers
NameTitle
Marc Funk Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP30.35%25 190
IQVIA HOLDINGS INC.26.16%28 671
CELLTRION, INC.--.--%19 692
INCYTE CORPORATION23.48%16 659
SEATTLE GENETICS, INC.47.16%14 006
EXACT SCIENCES CORPORATION58.07%12 282